Drug intelligence / Profile preview

JS122

Development stage: Preclinical
Lead developer: Junshi Biosciences
Modality: Small Molecules
Administration: Oral

Overview

JS122 is a small-molecule, second-generation irreversible selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) under development for oncology indications. It was in-licensed by Junshi Biosciences from Wigen Biomedicine as part of a portfolio of small-molecule anti-tumor drugs, including JS120 (IDH1 inhibitor), JS121 (SHP2 inhibitor), and JS123 (ATR inhibitor). Its highest disclosed development status is preclinical, with neoplasms listed as the therapeutic area. The drug is designed to covalently and selectively inhibit FGFR2 signaling, a pathway implicated in cancers with FGFR2 alterations such as fusions or mutations.[1][7]

Other names: JS-122JS122JS 122

Targets

FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on JS122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS122.

Explore the full profile